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Background: Gamabufotalin (CS-6), a major bufadienolide of Chansu, has been used for cancer therapy due to its
desirable metabolic stability and less adverse effect. However, the underlying mechanism of CS-6 involved in anti-tumor
activity remains poorly understood.
Methods: The biological functions of gamabufotalin (CS-6) were investigated by migration, colony formation and
apoptosis assays in NSCLC cells. The nuclear localization and interaction between transcriptional co-activator p300 and
NF-κB p50/p65 and their binding to COX-2 promoter were analyzed after treatment with CS-6. Molecular docking study
was used to simulate the interaction of CS-6 with IKKβ. The in vivo anti-tumor efficacy of CS-6 was also analyzed in
xenografts nude mice. Western blot was used to detect the protein expression level.
Results: Gamabufotalin (CS-6) strongly suppressed COX-2 expression by inhibiting the phosphorylation of IKKβ
via targeting the ATP-binding site, thereby abrogating NF-κB binding and p300 recruitment to COX-2 promoter.
In addition, CS-6 induced apoptosis by activating the cytochrome c and caspase-dependent apoptotic pathway.
Moreover, CS-6 markedly down-regulated the protein levels of COX-2 and phosphorylated p65 NF-κB in tumor
tissues of the xenograft mice, and inhibited tumor weight and size.
Conclusions: Our study provides pharmacological evidence that CS-6 exhibits potential use in the treatment of
COX-2-mediated diseases such as lung cancer.
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Lung cancer is a leading cause of human death world-
wide, and non-small cell lung cancer (NSCLC) com-
prises approximately 85% of all lung cancers. Although
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unless otherwise stated.improved in recent decades, poor prognosis of NSCLC
still leads to a less than 20% five-year survival rate of the
patients [1-3]. Therefore, novel therapy strategies are ne-
cessary to improve the survival rate of patients with lung
cancer.
NF-κB is a family of important transcriptional factors
known to regulate a wide range of biological effects,
including proliferation, metastasis and apoptosis, via
its downstream target genes [4,5]. NF-κB is seques-
tered in the cytoplasm in resting cells by the inhibitory
IκB proteins [6]. In response to a variety of stimula-
tion, IκB would be phosphorylated by the inhibitor of
κB (IKK) kinase complex and further be degradedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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releasing the active NF-κB dimmers. The free NF-κB
then binds to DNA and affects gene expression. There-
fore, inhibition of NF-κB activation might be an effect-
ive alternative approach to suppress cancer growth.
It has been well documented that COX-2 is a key en-
zyme involved in cancer development and progression,
and plays a central role in the modulation of tumor via-
bility, migration, invasion, and even inflammation [8-10].
COX-2, as the rate-limiting enzymes for the synthesis of
prostaglandins from arachidonic acid, is linked to the
carcinogenesis of many human cancers, including lung,
breast, colon, esophagus, head and neck cancers, and its
overexpression is highly related to the poor prognosis of
patients [11-16]. Its selective inhibitors could effectively
prevent inflammation, proliferation and angiogenesis,
and induce apoptosis in human cancer cells. In addition,
COX-2 expression is transcriptionally controlled by the
binding of multiple transactivators such as NF-κB and
coactivators such as p300 and p65 to the corresponding
sites of its promoters [17,18]. Thus, the signals to activate
NF-κB have been shown to induce COX-2 expression, im-
plying that the anti-cancer effect of drugs may be con-
comitant with the downregulation of COX-2 expression.
IKK including IKKα (IKK1) and IKKβ (IKK2), is the
convergency point in most signaling pathways activated
by many stimuli leading to the inducible phosphoryl-
ation and degradation of IκB proteins, thus activated
NF-κB. Some studies have clearly demonstrated that al-
though IKKα and IKKβ have a high degree of sequence
homology and share similar structural domains, IKKβ
has 20–50-fold higher level of kinase activity for IkB
than IKKα [19]. Thus, it is essential to identify a small-
molecule inhibitor selectively targeting IKKβ, and ex-
plore its mechanisms regulating NF-κB activation.
In recent years, increasing attentions have been paid
on some natural products that existing in traditional
Chinese medicines due to their great potential in various
cancer therapies [20]. Toad venom, called “Chansu” (CS)
in China, from the postauricular glands and skin of Bufo
bufo gargarizans Cantor [21,22] have been widely and
successfully used for centuries alone or in combination
with other herbal ingredients, as an anodyne, cardiotonic,
antimicrobial, local anesthetic, anti-inflammatory and an-
tineoplastic agent [23]. Gamabufotalin (CS-6, Figure 1A),
a major derivative of bufadienolides, had higher content of
1.75%-5%, and significant anti-tumor activity [24]. And
our previous work (data not shown) further supports its
stable metabolic property and less adverse effects when
compared with other bufadienolides. However, as a bio-
active molecular, the detailed anti-cancer mechanism of
CS-6 had not yet been characterized.
In this study, we investigated the mechanisms of CS-6
for COX-2 suppression in vivo and in vitro, and revealedthat CS-6 could target IKKβ to inactive NF-κB signaling
pathway and further down-regulate COX-2 expression.
Our findings therefore suggested that CS-6 would serve
as a potential candidate targeting IKKβ to suppress
COX-2 expression for anticancer treatment.
Materials and methods
Chemicals and reagents
Gamabufotalin (CS-6) was isolated from ChanSu by Dr.
Xiaochi Ma (Dalian Medical University, Liaoning,
China), which was secreted from the postauricular and
skin glands of Bufo bufo gargarizans Cantor. The crude
materials of ChanSu were purchased from Qingdao,
Shandong Province of China. And a voucher specimen
had been deposited at School of Pharmacy, Dalian Medical
University. A preparative high-speed counter-current chro-
matography (HSCCC) method for isolation and purifica-
tion of bufadienolides from ChanSu was developed by
using a stepwise elution with two-phase solvent system
composed n-hexane-ethyl acetate- methanol–water at the
ratios of 4:6:2:4 (v/v), 4:6:2.5:4 (v/v) and 4:6:3.2:4 (v/v). A
total of 38 mg of CS-6 was obtained in one-step separation
from 1.1 g of the crude extract with purity of 98.7%. Its
chemical structure was identified on the basis of 1H-NMR
and 13C-NMR technology. All organic solvents for HSCCC
separation and preparation of crude extract were the ana-
lytical grade (Beijing Chemical Factory, China). For our ex-
periments, the solution of CS-6 (1 μM) in dimethyl
sulphoxide (DMSO) was prepared and kept at −20°C, as
the stock solution. CS-6 was diluted in culture medium to
obtain the desired concentration, which was stable in the
dilution with DMSO concentration less than 0.1%. The
Phosphate Buffered Saline (PBS), protease inhibitor cock-
tail and 5-diphenyltetrazolium bromide (MTT) were pur-
chased from Sigma Chemical Co (St. Louis, MO).
Antibodies and other materials
The primary antibodies for COX-2, IKKα, IKKβ, p-IKKα/β,
IκB-α, p-IκB-α, cleaved caspase-9, NF-κB p65 and p-p65,
β-actin and all the secondary antibodies were obtained from
Cell Signaling Technology (Cell Signaling Technology, Inc,
USA). The primary antibodies for GAPDH, p300, NF-κB
p50, and cytochrome c were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Trypsin, Dul-
becco’s Modified Eagle’s Medium (DMEM), RPMI 1640
and fetal bovine serum (FBS) were obtained from HyClone
Laboratories (HyClone Laboratories Inc.). All other chemi-
cals were purchased from Sigma Chemical Co. (St. Louis,
MO) unless otherwise specified.
Cell culture
Human NSCLC H1299, A549, H322 and H460 cell lines
and human embryonic lung fibroblasts HLF cell line
were obtained from ATCC (Manassas, VA). Cells were
Figure 1 CS-6 inhibited cell viability and changed morphology. (A) Chemical structure of CS-6. (B, C) Human lung cancer A549, H1299, H322
cells and human embryo lung fibroblast (HLF) cells were treated with CS-6 under normal culture medium at the indicated doses. (B) The changes
in cell morphology and spreading in A549 cells treated with CS-6 for 48 h were observed and cells were photographed using a microscope fitted
with digital camera. (C) At 48 hours after treatment, the cell viability was determined by a MTT assay. The data are presented as mean ± SD of
three tests. (*P < 0.05,**P < 0.01, significant differences between CS-6treatment groups and DMSO vehicle control groups).
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medium supplemented with 10% fetal bovine serum. All
cell cultures were maintained at 37°C in a humidified at-
mosphere containing 5% CO2.Cell viability assay
Cell viability was determined by a MTT assay (Roche
Diagnosis, Indianapolis, IN). Briefly, lung cancer cell
lines were seeded at 6 × 103 cells/well in 96-well plates.
Cells were allowed to adhere for overnight, and then the
cells were changed to fresh medium containing various
concentrations of CS-6 (0, 10, 50 and 100 nM) dissolved
in DMSO (final concentration, 0.1%). After 48 h incuba-
tion, the growth of cells was measured. The effect on cell
viability was assessed as the percent cell viability com-
pared with untreated control group, which were arbitrarily
assigned 100% viability. The CS-6 concentration required
to cause 50% cell growth inhibition (IC50) was determined
by interpolation from dose–response curves. All experi-
ments were performed in triplicate.In vitro migration assay
Scratch assay (wound healing assay) was performed to
detect cell migration. The cells were grown to full con-
fluence in six-well plates and wounded with a sterile 100
ul pipette tip after 6 h of serum starvation and then
washed with starvation medium to remove detached
cells from the plates. Cells were treated with indicated
doses of CS-6 in full medium and kept in a CO2 incuba-
tor. After 48 h, medium was replaced with phosphate
buffered saline (PBS) buffer, the wound gap was ob-
served, and cells were photographed using a Leica DM
14000B microscope fitted with digital camera.Colony formation assay
To analyze the cell sensitivity to CS-6, we used a colony
formation assay in vitro. Briefly, A549 cells (0.8 × 103 per
well) were seeded in six-well plate containing 2 ml
growth medium with 10% FBS and cultured for 24 h.
Then, removed the medium, and cells were exposed to
various concentrations of CS-6 (0, 10, 50 and 100 nM).
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mented fresh medium containing 10% FBS. The cultures
were maintained in a 37°C, 5% CO2 incubator for
14 days, allowing viable cells to grow into macroscopic
colonies. Removed the medium, and the colonies were
counted after staining with 0.1% crystal violet.
Apoptosis assay
Apoptosis was measured by fluorescence-activated cell
sorter (FACS) using the Annexin V- FITC Apoptosis De-
tection Kit (Nanjing KeyGEN Biotech. CO., LTD.). In
brief, cells plated in 6-well plates were treated with CS-6.
After treatment of 12 h, cells were collected and washed
once with cold PBS, and subsequently stained simultan-
eously with FITC-labeled annexin V and PI. Stained
cells were analyzed using FACS Accuri C6 (Genetimes
Technology Inc.).
Western blot analysis
Cell lysate proteins were separated by electrophoresis on
a 7.5-12% sodium dodecyl sulfate-polyacrylamide mini-
gels (SDS-PAGE) and then electrophoretically trans-
ferred to a PVDF membrane. Western blots were probed
with the specific antibodies. The protein bands were de-
tected by enhanced chemiluminescence. Similar experi-
ments were performed at least three times. The total
protein concentration was determined using a BCA pro-
tein assay kit.
Confocal immunofluorescence
Immunofluorescence staining was done in cells cultured
in chamber slides. After CS-6 treatment, the cells were
washed in phosphate-buffered saline (PBS) and fixed for
10 min at room temperature (RT) with 4% paraformal-
dehyde. The samples were permeabilized with 0.2%
TritonX-100 for 5 min. And then blocked with 10% bo-
vine serum albumin (BSA) in PBS for 30 min. Anti-
bodies against Cytochrome c, p65, p50, and p300 in the
1% blocking solution were added to the sample and incu-
bated for overnight at 4°C. Following three 10-min washes
with PBS, fluorescein isothiocyanate- and rhodamine-
conjugated secondary antibodies were added in 1% block-
ing solutions and incubated for 1 hr. Subsequently, the
stained samples were mounted with 4′, 6-diamidino-2-
phenylindole (DAPI)-containing Vectashield solution
(Vector Laboratories Inc.) to counterstain cell nuclei.
After five additional 5-min washes, samples were ex-
amined with a Leica DM 14000B confocal microscope.
DNA-protein binding by streptavidin-agarose pulldown
assay
Binding of p300 or p65, p50 NF-κB to COX-2 core pro-
moter probes were determined by a streptavidin-agarose
pulldown assay. A biotin-labeled double-stranded probecorresponding to COX-2 promoter sequence was syn-
thesized. The binding assay was performed by mixing
400 μg of nuclear extract proteins, 4 μg of the biotinylated
DNA probe and 40 μl of 4% streptavidin-conjugated agar-
ose beads at room temperature for 5 h in a rotating
shaker. Beads were pelleted by centrifugation to pull down
the DNA-protein complex. DNA-bound p300 or p65, p50
NF-κB protein was dissociated by boiled in 30 μl of 2X
Laemmli sample buffer and analyzed by Western blotting.
Reverse transcription-polymerase chain reaction (RT-PCR)
Z138 cells were treated with different concentrations of
CS-6 (0, 10, 50, and 100 nM) for 48 h and then har-
vested. Total cellular RNA was extracted using the
RNAiso Plus reagent, according to the manufacturer’s
protocol (TaKaRa Biotechnology, Dalian, China). Total
RNA (1.5 ug) was reverse-transcribed using the Prime-
ScriptTM RT-PCR Kit (TaKaRa). PCR analysis was per-
formed on aliquots of the cDNA preparations to detect
gene expression. PCR was programmed as follows: 5 min at
95°C followed by 35 cycles (30 for GAPDH), 30 s at 94°C,
30 s at 60°C, and 1 min at 72°C. RT-PCR products were ana-
lyzed via 1.0% agarose gel electrophoresis and stained with
Gold View for visualization using ultraviolet light.
Quantitative real-time reverse transcription polymerase
chain reaction (RT-qPCR)
Total RNA was extracted from A549 cells after treat-
ment with CS-6 for 48 h, using TRIzol reagent according
to the kit protocol (TaKaRa Bio, Dalian, China). cDNA
was reverse-transcribed using the PrimeScript RT Re-
agent Kit (TaKaRa Bio, Dalian, China) according to the
manufacturer’s instructions. The Q-PCR reaction was per-
formed following the kit protocol (TaKaRa Bio, Dalian,
China), and amplification was performed using the
Mx3005P Real-Time PCR System (Agilent, CA, USA).
The relative mRNA expression of each gene was nor-
malized to GAPDH RNA levels and analyzed using the
2−ΔΔCT method. The primers were synthesized by invi-
trogen (Shanghai, China). The primers for COX-2 were:
5′-TCACAGGCTTCCATTGAC CAG-3 and 5′-CCGAG




The chromatin immunoprecipitation (ChIP) assay was
performed as previously described. In brief, about 80%
confluent cells were used for the experiments after ex-
posed to CS-6 for 48 h. 1% paraformaldehyde was added
to the cell-culture medium to cross-link, and after incuba-
tion for 10 min at 37°C with gently shaking, the cells were
washed twice in cold phosphate-buffered saline, scraped,
and lysed in lysis buffer (1% SDS, 10 mM Tris–HCl,
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tin A, and aprotinin) for 10 min at 4°C. The lysates were
sonicated five times for 15 s each time, and the debris was
removed by centrifugation. A 20-μl aliquot was removed
to serve as an input sample. The remaining of the lysate
were diluted 10-fold with a dilution buffer (0.01% SDS, 1%
Triton X-100, 1 mM EDTA, 10 mM Tris–HCl, pH 8.0,
and 150 mM NaCl) followed by incubation with anti-
bodies against specific transactivators or a nonimmune
rabbit IgG control overnight at 4°C. Immunoprecipitated
complexes were collected using protein A/G plus agarose
beads. The precipitates were extensively washed and incu-
bated in an elution buffer (1% SDS and 0.1MNaHCO3) at
room temperature for 20 min. Cross-linking of protein–
DNA complexes was reversed at 65°C for 5 h, followed by
treatment with 100 ug/mL proteinase K for 2 h at 37°C.
DNA was extracted three times with phenol/chloroform
and precipitated with ethanol. The pellets were resus-
pended in TE buffer and subjected to PCR amplification
using specific COX-2 promoter primers (Forward primer:
ACGTGACTTCCTCGACCCTC, and Reverse primer:
AAGACTGAAAA CCAAGCCCA). The resulting prod-
uct of 478 bp for COX-2 in length was separated by 1.0%
agarose gel electrophoresis.
Molecular modeling
The molecular docking studies were performed to ex-
plore the potential binding mode between CS-6 and
IKKβ protein complex. CS-6 was optimized using the
semi-empirical PM3 method with the Polak-Ribie’re
conjugate gradient algorithm with an RMS gradient of
0.01 kcal mol−1 Å−1 as convergence criterion. The opti-
mized structure of CS-6 was docked into the active site
of IKKβ with ligand K-252A (PDB Code: 4KIK). The
crystallographic ligand was extracted from the active
site, and the residues within a 6.5 A° radius around IKKβ
molecule were defined as the active pocket. The Surflex-
Dock program was used for the docking calculations
with default parameters. MOLCAD surfaces were gener-
ated for visualizing the binding mode of the docked
protein–ligand complexes.
Animal studies
All animals were maintained, and animal experiments
were done in SPF Laboratory Animal Center at Dalian
medical university. The animals used in this study were
female nu/nu mice (4–6 weeks old). To evaluate the
therapeutic efficacy of CS-6 in a human A549 orthotopic
lung cancer mouse model, A549 cells (2 × 106 in 100 μL
PBS) were injected subcutaneously near the axillary fossa
of the nude mice using a 27-gauge needle. The tumor
cell–inoculated mice were randomly divided into three
treatment groups that each contained five mice. Two
weeks later, when the tumor diameters reached 3 mm ×4 mm, group A was treated with PBS; group B with 100
ug/20 g CS-6; group C with 100 ug/20 g CS-6 by intra-
peritoneal injection every day. Tumors were measured
with a caliper every 2 days, and the tumor volume was
calculated using the formula V = 1/2 (width2 × length).
Body weights were also recorded. On day 30 after tumor
cell inoculation, all experimental mice were terminated
with ether anesthesia and the total weight of the tumors
in each mouse was measured. To determine COX-2 or
p65 NF-κB expression, the tumor tissues were harvested
and freshly fixed with 10% neutral formalin and desic-
cated and embedded in paraffin. 4 μm sections were
stained with hematoxylin and eosin, COX-2 antibody
(1:80) and p-p65 NF-κB (1:150) antibody, and examined
under a light microscope. The images were examined
under a Leica DM 4000B fluorescence microscope equipped
with a digital camera.
All animal maintenance and procedures were carried
out in strict accordance with the recommendations
established by the Animal Care and Ethics Committee of
Dalian Medical University as well as the guidelines by
the U.S. National Institutes of Health Guide for the Care
and Use of Laboratory Animals. The protocol was ap-
proved by the Animal Care and Ethics Committee of
Dalian Medical University. In animal study, all efforts
were made to minimize suffering of mice. All mice were
humanely sacrificed by ether anesthesia inhalation before
death.Statistical analysis
All experiments were repeated three times. Data are rep-
resented as mean ± standard deviation (SD). Analysis of
variance and Student’s t-test were used to compare the
values of the test and control samples in vitro and
in vivo. P < 0.05 was considered to be a statistically sig-
nificant difference. SPSS 17.0 software was used for all
statistical analysis.Results
CS-6 inhibited NSCLC cell proliferation and changed cell
morphology
Cell viability plays an essential role in carcinogenesis,
and its inhibition is crucial to treat cancer [25]. Firstly,
we quantitatively examined the effect of CS-6 (Figure 1A)
on cell morphology and cell proliferation of several hu-
man lung cancer cell lines by MTT assay. As shown in
Figure 1B, CS-6 markedly reduced cell-to-cell contact
and had lower spreading with fewer formation of filo-
podia compared with the DMSO vehicle control groups.
Interestingly, treatment with CS-6 resulted in the dose-
dependent growth inhibition of NSCLC cells, but has no
cytotoxicity in human normal lung cell line (HLF cells)
at the same dose (Figure 1C).
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NSCLC cells
Clonogenic cell survival assay was employed to evaluate
the influence of CS-6 on the clonogenic capacity of
A549 cells. Consistent with cell proliferation inhibition,
CS-6 also significantly inhibited colony formation and
resulted in a remarkable decrease at colony formation
ratio (Figure 2A). Wound-healing assay further revealed
the inhibition effect of CS-6 on tumor cell mobility in
A549 and H1299 cells. As shown in Figure 2B, the part
of gap or wounding space between cell layers after
making a scratch was occupied almost (in A549 cells)
or completely (in H1299 cells) by the migrating cells
after 48 h in the control group. By contrast, the CS-6
treated cells failed to occupy the scraped space through
migration due to their impaired migration capability.
Quantitative analysis revealed that the inhibition of
migration was in a dose-dependent manner. These re-
sults suggest that CS-6 has the perfect properties in
suppressing cell colony formation and migration for
NSCLC cells.Figure 2 CS-6 suppressed cell colony formation and migration. (A-B)
doses for appropriate time. (A) The tumor cell A549-induced colony forma
(B) Cell migration was analyzed by a wound-healing assay. A549 and H129
migration was measured as described in Section 2, and the migration rate
separate experiments. (*P < 0.05,**P < 0.01, significant differences betweeCS-6 induced apoptosis via modulating cytochrome c and
caspase signaling
Apoptosis is a cell suicide mechanism that enables or-
ganisms to control cell numbers and eliminate malignant
cells that threaten survival [26]. Induction of apoptosis
in target cells is a key mechanism for anti-cancer ther-
apy [27]. We next determined whether the enhancement
of cell growth inhibition induced by CS-6 is associated
with the increase of apoptosis in lung cancer cells. We
conducted a time-course study for the effect of CS-6 on
apoptosis using two effective concentrations. The results
showed that CS-6 treatment resulted in a significant
dose-dependent induction of apoptosis in A549 cells.
We also found that the induction of apoptotic cells by
CS-6 had significant difference between 12 h and 24 h
or 48 h, but had no difference between 24 h and 48 h.
To make sure the effect of CS-6 on cell apoptosis,
then we detected the expression of three key pro-
apoptotic proteins (PARP, caspase-3, caspase-9) in both
A549 and H1299 cells by Western blot analysis. CS-6
could markedly increase the expression levels of theHuman A549 and H1299 cells were treated with CS-6 at the indicated
tion was also analyzed, and the colony formation rate was calculated.
9 cells were seeded in 6-well plates and grown to full confluence. Cell
was calculated. The data are presented as the mean ± SD of three
n CS-6treatment groups and DMSO vehicle control groups).
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pared with the control group (Figure 3B). Additionally,
some evidences had pointed out that the release of cyto-
chrome c (cyt c) from mitochondria into cytosol is a
critical step in the activation of apoptosis [28]. Many
apoptotic stimuli induce cyt c release from the mito-
chondrial intermembrane space into the cytosol, thereby
inducing apoptosis. We next monitored the changes in
the subcellular localization of cyt c in A549 and H1299
cells to determine whether CS-6 could induce cyt c re-
lease by employing immunofluorescence imaging (IF)
analysis. As shown in Figure 3C, treatment with CS-6
(10 nM or 50 nM) markedly triggered the release of cyt c
from mitochondria to cytosol. These results demonstrated
that CS-6 could induce NSCLC cell apoptosis through
triggering cyt c release from mitochondria and facilitatingFigure 3 CS-6 induced apoptosis by modulating cytochrome c/caspas
doses. Treatment with CS-6 in a time-course manner, the apoptosis was de
caspase-3/9, cleaved PARP proteins in A549 and H1299 cells was analyzed
determined by immunofluorescence imaging analysis to monitor Cytc rele
(C). The apoptosis is represented by relative percentages of apoptotic ce
differences between CS-6 treatment groups and DMSO vehicle control g
group and 12 h treatment group).the downstream apoptosome assembly and caspase activa-
tion in the cytosol.
CS-6 suppressed COX-2 expression in NSCLC cells
COX-2 expression has been demonstrated to induce cell
proliferation, migration, and angiogenesis in cancer cells.
To determine whether CS-6 influenced COX-2 signaling
in lung cancer cells, expression level of COX-2 gene and
protein in the CS-6 treated cancer cells was detected by
RT-PCR, RT-qPCR and Western blot, respectively. As
shown in Figures 4A,B and C, the CS-6 effectively inhib-
ited COX-2 expression at both protein and mRNA levels
in A549 cells in a dose-dependent manner. To deter-
mine whether CS-6 also inhibited COX-2 expression in
other NSCLC cells, we treated H322 and H460 cells with
CS-6 at different doses, and found that CS-6 alsoe signaling. Human A549 cells were treated with CS-6 at the indicated
termined by a FACS analysis (A), and the levels of the cleaved
by Western blot (B). The release of Cytc in A549 and H1299 cells was
ase from the mitochondrial intermembrane space into the cytosol
lls versus that in DMSO-treated cells. (*P < 0.05,**P < 0.01, significant
roups; #P < 0.05, ##P < 0.01, significant differences between 48 h treatment
Figure 4 CS-6 suppressed COX-2 expression. (A–C), Human A549, H322, H460 cells were treated with CS-6 at the indicated doses. At 48 h after
treatment, expression levels of COX-2 protein and gene were analyzed by Western blotting (A), RT-PCR (B) and RT-qPCR (C) in A549 cells, respectively.
(D) At 48 h after treatment, the COX-2 protein levels were analyzed by Western blotting in H322 and H460 cells. GAPDH was used as controls for sample
loading. (E) A549 cells were pretreated with the COX-2-selective inhibitor celecoxib (CB, 25 uM and 50 uM) for 8 h and then treated with CS-6 (50 nM).
At 48 h after treatment, cell viability was determined by MTT analysis. The percent cell viability was calculated relative to the cells treated with the
DMSO vehicle control. The data are presented as the mean ± S.D. of three separate experiments. (*P < 0.05,**P < 0.01, significant differences
between CS-6treatment groups and DMSO vehicle control groups). (F) A549 cells were pretreated with the COX-2 inhibitor celecoxib (CB,
50 uM) and inducer pyromellitic acid (PMA, 200 nM) for 8 h and then treated with CS-6 (50 nM). The protein levels of COX-2, the expression
of cleaved caepase-3 were analyzed by Western blot.
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both H322 and H460 cells.
To further confirm the role of CS-6 in regulating the
COX-2 signaling in lung cancer cells, A549 cells were
treated with CS-6 (50 nM) after COX-2-selective inhibitor
celecoxib (CB, 25 uM and 50 uM) pretreatment at 8 h.
After continuous incubation of 48 h, the cell proliferation
was analyzed by a MTT assay. As shown in Figure 4E,
treatment of cells with different dosage of CB alone has
different inhibitory effect on cell viability, however, the
combined treatment with CS-6 (50 nM) and CB did not
markedly affect the cell viability compared with CS-6
treatment alone. These results suggested that CS-6 might
also partially inhibit the activation of the COX-2 signaling,
thereby affecting cell viability.
To see whether there was a correlation between the
COX-2 inhibition and apoptosis induction mediated byCS-6 in NSCLC cells, we co-treated A549 cells with CS-
6 in combination with a COX-2 inhibitor (CB) or a
COX-2 inducer (PMA), and then analyzed the expres-
sion of COX-2 and the apoptosis-related protein (cleaved
caspase-3) by Western blot. The results showed that treat-
ment of A549 cells with the COX-2 inhibitor (CB) or in-
ducer (PMA) didn’t markedly affect the expression levels
of the cleaved caspase-3, suggesting that there was no
obvious correlation between the CS-6-mediated COX-
2 inhibition and apoptosis induction in NSCLC cells
(Figure 4F).
CS-6 inhibited NF-κB and p300 translocation and binging
to COX-2 promoter
Previous reports suggested that NF-κB is an important
transcription factor that regulates the expression of
COX-2 and inflammatory cytokines [4,29], the region of
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NF-κB [30,31], and transcriptional coactivator p300 can
bind to promoter-bound transactivators such as NF-κB
to regulate COX-2 gene expression in cancer cells. We
next performed immunofluorescence assay to confirm
the nuclear localization and interaction between p300
and NF-κB in A549 cells. Constitutive translocation of
NF-κB p50/p65 and coactivator p300 to the cell nucleus
and the colocalization of p50 with p65 and p300 were
detected in A549 cells. Treatment with CS-6 markedly
inhibited translocation of the NF-κB p65/p50 proteins from
cell cytoplasm to nucleus and caused p300 into the cyto-
plasm by comparison with the DMSO control (Figure 5A).
The results indicate that the inhibition of A549 cell prolif-
eration by CS-6 might be mediated by inhibiting NF-κB
and p300 translocation form cell nuclei to cytoplasm to fur-
ther inhibit COX-2 expression.
We further evaluated the effect of CS-6 on the binding
activities of NF-κB and p300 on COX-2 promoter byFigure 5 CS-6 inhibited NF-κB and p300 translocation and their bingi
CS-6 at the indicated doses. (A) At 12 h after treatment, the subcellular loc
or p300 were examined by confocal microscopy analysis with a confocal m
cells with typical morphology were presented. (B) At 12 and 48 h after trea
was analyzed by a streptavidin-agarose pulldown assay. (C) At 48 h after tr
antibodies to p50, p65, and p300, and the COX-2 promoter region in the pstreptavdin-agarose pulldown (Figure 5B) and ChIP assay
(Figure 5C). The results showed that treatment of cells
with CS-6 for 12 h or 48 h markedly inhibited the binding
of NF-κB p50 and p65 subunits to the COX-2 promoter
DNA probe (Figure 5B) or to the COX-2 promoter in
chromatin structure (Figure 5C) in a dose-dependent man-
ner as compared with the control treatment. Moreover, we
found that p300 bound to the NF-κB responsive element
region of the COX-2 promoter as a co-activator, while CS-
6 treatment also dose-dependently inhibited the binding of
p300 to the COX-2 promoter at 12 h or 48 h treatment.
These results suggest that the inhibition of COX-2 expres-
sion by CS-6 might be mediated by modulating the
NF-κB/p300 signaling pathway in lung cancer cells.
CS-6 inhibited IKKβ activity by targeting the ATP binding
site
Since IκB kinase (IKK) complex is required for NF-κB ac-
tivation, and its one member, IKKβ, is a major upstreamng to COX-2 promoter. (A-C) Human A549 cells were treated with
alization of p50, p65, and p300 and the colocalization of p65 with p50
icroscope. More than 100 cells were inspected per experiment, and
tment, the binding of p300, p65 and p50 to COX-2 promoter probe
eatment, chromatin in the treated cells was immunoprecipitated with
recipitated chromatin was amplified by PCR.
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we then investigated whether CS-6 exert some influence
on IKK activity with an aim to better understand the re-
lated molecular events.. As shown in Figure 6A, pretreat-
ment with CS-6 not only significantly suppressed the
phosphorylation of p-IKKβ in A549 cells without affecting
their overall IKKβ expression, but also decreased the ex-
pression level of p-IκB-α. Thereafter, we hypothesized that
CS-6 might bind to IKKβ and subsequently inhibited its
kinase activity. To test this hypothesis, computer molecu-
lar modeling assay was conducted to simulate the interac-
tions between CS-6 and IKKβ. Molecular docking studies
predicted that CS-6 could bind to ATP binding site of
IKKβ. Specifically, as shown in Figure 6B (Left), CS-6
formed three hydrogen bonds with the ATP binding
pocket of the IKKβ kinase domain. The CO motif at the
lactonic ring of CS-6 forms a hydrogen bond with the
backbone NH of Cys99. The OH group at the C-30 pos-
ition forms an additional hydrogen bond to the carbonyl
oxygen of Glu149. Moreover, the OH group at the C-14
position accepts a hydrogen bond with the CO of Asn28.
The result of MOLCAD surface modeling indicated that
the lacton ring of CS-6 extends into the deep hydrophobic
cavity of the ATP-binding pocket (Figure 6B, Right). As
expected, both p-p65 expression level in cytoplasmic andFigure 6 CS-6 inhibited the phosphorylation and activation of IKKβ. (
48 h after treatment, the IKKβ, p-IKKβ, IκBα and p-IκBα proteins were analyz
binding site of IKKβ generated with docking. (Left) Interactions of CS6 and
as yellow dashed lines, and the participating amino acid residues are mark
surface upon the bioactive pose of CS6 in the ATP binding site of IKKβ. Th
corresponds to the neutral moiety. (C) Cytoplasmic and nuclear extracts
GAPDH and TFIIB were used as controls for sample loading. (D) A549 cells w
IKKβ, and p-IKKβ proteins were analyzed by Western blotting.p65, p50 expression in nuclear decreased significantly
after CS-6 treatment (Figure 6C). All of these results sup-
ported that IKKβ was a target of CS-6 in the NF-κB sig-
naling pathway to suppressed COX-2 expression.
Since CS-6 targets IKKs to suppress COX-2 expression
and CB is a COX-2-selective inhibitor, we next detected
the combined effect of CS-6 and CB on IKK signaling.
The A549 cells were pre-treated with CB (50 uM) for
8 h and then treated with CS-6 (50 nM) for 48 h. As
shown in Figure 6D, the combined treatment of CB and
CS-6 effectively decreased the level of p-IKKβ without
affecting the total IKKβ expression. This effect was simi-
lar to CS-6. These results suggest that CS-6 might be an
inhibitor of COX-2 like CB.
CS-6 inhibited the growth of lung cancer xenografts in
nude mice
Based on the results of in vitro studies, we further ex-
plored the potential of CS-6 as a novel molecular thera-
peutic agent for tumor growth in mice with human lung
cancer xenografts. Mice bearing subcutaneous tumors
were treated with therapy 14 d after tumor cell injection.
Mice were divided into three treatment groups. After ad-
ministration of CS-6 at 5 and 20 mg/kg/day in the mice
with A549-xenografts for 17 days, both the tumorA) Human A549 cells were treated with CS-6 at the indicated doses. At
ed by Western blotting. (B) The best ranked pose of CS6 in the ATP
IKKβ are delineated by ribbon structure, Hydrogen bonds are displayed
ed. (Right) MOLCAD representation the molecular lipophilic potential
e blue denotes the hydrophilic, brown for the lipophilic and green
were prepared for the Western blot analysis of p-p65, p65 and p50.
ere treated with CS-6 (50 nM) after pretreatment with CB (50 nM). The
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http://www.molecular-cancer.com/content/13/1/203volume (Figure 7A) and the tumor weights (Figure 7B)
in the treated mice decreased significantly when com-
pared with those in the control group. No obvious toxic
effects in mice treated by CS-6 were detected. In
addition, H&E staining also showed that the untreated
tumor cells were irregular and had abundant cytoplasm,
large and deformity nuclei and high nucleocytoplasmic
ratio. The nuclear pleomorphism and nucleolus wereFigure 7 CS-6 inhibited tumor growth in lung cancer mouse models.
evaluate the effect of CS-6. Tumor volumes (A) and total weights (B) were
COX-2 and p-p65 protein expression in tumor samples. Neutral formalin fix
immunohistochemical staining with rabbit anti-rabbit second antibody usiprominent. It could be also seen amphinucleolus and
mitotic (Figure 7C). However, in treatment group tumor
cells, it was rarely seen amphinucleolus and mitotic, and
the nucleolus was smaller and more regular (Figure 7C).
Moreover, the immunohistochemical staining assay was
used to determine the expression of COX-2 and p-p65.
The expression levels of COX-2 and p-p65 were sig-
nificantly decreased with CS-6 treatment in vivo, asAn orthotopic mouse model of human NSCLC A549 was used to
measured. (C) H&E staining. (D). Immunohistochemical analysis of
ed tumor samples were prepared from animals and analyzed by
ng the Vectastain Elite ABC kit, and examined under a microscope.
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results supported that CS-6 could inhibit the xeno-
grafted human lung cancer cell’s growth without the
remarkable adverse effects.
Discussion
Toad Venom, a traditional Chinese medicine (TCM), is
an anti-inflammatory drug used in small doses for the
treatment of various types of inflammation in China
[32,33]. Bufadienolides, such as bufalin and cinobufagin
as its major active ingredients, exhibited the significant
antitumor activities, including inhibition of cell prolifera-
tion, induction of apoptosis, inhibition of cancer angio-
genesis, and regulation of the immune response [32].
Meantime, Toad Venom extracts or bufadienolides also
exhibited the significant anti-inflammatory action by
inhibiting the proliferations of human T-lymphocytes
[33]. However, there is little known about the biological
effects of other toad venom ingredients in vivo and
in vitro. Gamabufotalin (CS-6) is a major bufadienolide
with better drug ability, but only few researches have
studied on its biological activities.
In the present study, we found that gamabufotalin
(CS-6) could effectively inhibit NSCLC cells growth and
enhance apoptosis induction dose-dependently with IC50
of only 50 nM, while CS-6 nearly had no adverse effect
on human normal lung tissue cells at the dosage of
10 μM. Furthermore, we showed that the effects of CS-6
on lung cancer cells growth and apoptosis were medi-
ated through inhibiting NF-κB/COX-2 signaling pathway
and activating the cytochrome c/caspase-dependent apop-
totic pathway. CS-6 inhibited COX-2 expression through
suppressing the phosphorylation of IKKβ by targeting the
ATP-binding site, thereby inhibiting translocation of the
NF-κB p65/p50 proteins from cell cytoplasm to nucleus
and abrogating NF-κB binding and p300 recruitment on
COX-2 promoter. Here, to the best of our knowledge, it
might be the first time to report the treatment of CS-6 on
COX-2 expression and to demonstrate the underlying
mechanisms both in vitro and in vivo.
In our study, considering that A549 cell line overex-
presses COX-2 and has a higher ability to form xenograft
in nude mice, we performed almost in vitro experiments
in A549 cells to study the molecular mechanism of CS-6
suppressing COX-2 expression.
One of the pivotal roles in the inflammatory processes is
cyclooxygenase-2 (COX-2), an inducible enzyme, which
can be rapidly induced by inflammatory mediators, cyto-
kines, growth factors and tumour promoters [34-36]. Pre-
vious studies have shown that COX-2 overexpression has
a significantly central role to in cancer development by
promoting cell proliferation, decreasing apoptosis rate,
and increasing invasive and metastatic potential of the pri-
mary tumor [37-39]. To clarify the mechamism of CS-6from Chansu used as an anti-cancer agent, we investigated
whether COX-2 plays an important role in CS-6 bioactive
function, and found CS-6 could inhibit COX-2 expression,
along with inhibiting NSCLC viability, migration and col-
ony formation.
The transcription factor NF-κB has been shown to be
involved in COX-2 expression in various cell types [40].
Transcriptional coactivator p300 could increase the tran-
scriptional activity of the NF-κB complex through modi-
fication of chromatin structure and the direct acetylation
of p65 and p50 [41]. These evidences suggested that the
activation of NF-κB complex p300 played an important
role in bridging the multiple DNA-bound transactivators
with transcription factors to initiate COX-2 transcrip-
tion. In our study, we confirmed the nuclear localization
and interaction of NF-κB and p300 in lung cancer cells,
and found that CS-6 inhibited NF-κB translocation from
cytosol to nuclear and its binding to COX-2 promoter,
abrogating COX-2 transcriptional activation, thereby re-
duce COX-2 expression. In our study, we found that
CS-6 inhibited COX-2 expression and induced apop-
tosis; however, no direct correlation between them was
observed.
NF-κB is kept in an inactive state in the cytoplasm by
interacting with members of the IκB family of proteins
which mask the nuclear translocation signal of NF-κB
[42]. Upon stimulation, IκB proteins become phosphory-
lated at Ser32 and Ser36 residues by the inhibitor of κB
(IKK) kinase complex, ensuing degradation. Therefore,
IKK is essential to NF-κB activation. Next, we studied
whether CS-6 could affect IKK activity. Our present
study strongly indicated that CS-6 could inhibit serine
phosphorylation of IKKβ in a dose-dependent manner.
Moreover, computational docking implied that CS-6 oc-
cupied the deep hydrophobic pocket in the ATP-binding
site of IKKβ. In this modeling analysis, CS-6 located well
in the ATP binding site and interacted with the hinge re-
gion backbone residue Cys99, and also makes hydrogen
bond interaction with Glu149, same as K-252A, which
may be another reason for higher inhibition activity
[43,44]. Our results suggested that CS-6 might block the
nucleotide recognition domain binding with ATP, as a
reversible inhibitor. This is just consistent with our ex-
perimental results. Hydrophobic interactions should be
emphasized because the ATP binding pocket is consisted
of a narrow and hydrophobic region. These data men-
tioned above suggested that CS-6 may attenuate the
transcriptional activity of NF-κB, at least in part, by ab-
rogating the activity of IKKβ. IKKα and IKKβ are the
two catalytic subunits of IKK, and have a high degree of
sequence homology and share similar structural do-
mains. However, previous studies have clearly demon-
strated that IKKβ subunits of IKK complex are required
for NF-κB activation by all known pro-inflammatory
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IL-1β [45,46]. Thus, we mainly focus on the effect of
CS-6 on IKKβ in the present study.
In conclusion, we found that CS-6 suppresses COX-2
expression in lung cancer, both in vivo and in vitro.
Mechanistic investigation reveals that CS-6 may target
IKKβ signaling cascades. These findings provide strong
evidences for potential of CS-6 to be a novel anti-cancer
agent in NSCLC treatment.
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